User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

923

Interactions with Platform & by Email *

INTERACTIONS

183

Unique # Participated *

PARTICIPANTS

37

Responses Validated *

VALIDATIONS

12

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   A Quick Primer.....II-1
Why GPCRs Are Important?.....II-1
Untapped Pharmacological Potential of GPCRs Ignites Interest.....II-1
1$100
   Popular Types of GPCRs of Therapeutic Interest Currently Being Studied
  Include:.....II-2
Current Knowledge of GPCR Crystal Structures Just the Tip of the Iceberg.....II-2
1$100
   NMR Spectroscopy: An Invaluable Tool to Study GPCR Structures.....II-3
Orphan GPCRs: A Promising Area for Drug Discovery.....II-3
Developments in Screening Technology for GPCRs.....II-3
1$100
   Cell Membrane Assays for GPCR Quantitative Analysis.....II-4
What’s in for the Pharmaceutical Industry?.....II-4
1$100
   Challenges Aplenty in the GPCR Space.....II-5
Addressing Orphan GPCRs.....II-5
Lack of Structural Information.....II-5
Identification and Classification of Allosteric Sites.....II-5
1$100
   GPCR: Gateways to Cell.....II-6
Classification of GPCRs.....II-6
1$100
   Table 1: Number of Identified Known and Orphan (Non-Sensory) GPCRs in Human Genome (includes corresponding Graph/Chart).....II-7
Orphan GPCRs and Deorphanization.....II-7
1$350
   List of Select oGPCR-Ligand Pairings Identified By Using Reverse Pharmacology
  Approach (1990-2004).....II-8
Structural Information.....II-8
1$100
   Rhodopsin: A Well Studied GPCR.....II-9
Crystal Structure of Human Beta-2 Adrenergic GPCR.....II-9
Structure of Human A2A Adenosine Receptor.....II-9
1$100
   Significance of GPCR Crystal Structures.....II-10
GPCR Signaling Pathways.....II-10
Physiological Roles Performed by GPCRs.....II-10
Visual Sense.....II-10
Cell-density Sensing.....II-10
Regulation of mood and behavior.....II-10
Smelling Sense.....II-10
Regulating Immune-System Inflammation and Activity.....II-10
1$100
   Automatic Transmission of Nervous System.....II-11
Receptor – Ligand Interaction.....II-11
Types of Ligands.....II-11
Therapeutic Potential of GPCRs.....II-11
1$100
   Major Disease States and Associated Known GPCRs.....II-12
Allosteric Modulators and Implication of Allostery in Drug Discovery.....II-12
Advantages of Allosteric Modulators.....II-12
1$100
   Dimerisation and Role of Dimers in Drug Discovery.....II-13
Oligomerisation and Role of Oligomers in Drug Discovery.....II-13
Functional Selectivity.....II-13
Drug Candidates in GPCR Space.....II-13
1$100
   Select GPCR-Based Drugs Along with Target Receptor and Indication.....II-141$100
   Pipeline GPCR Drug Candidates.....II-15 1$100
   Table 2: GPCR Pipeline by Therapeutic Area: Percentage Breakdown of GPCR Molecules under Development for CNS, Oncology, Cardiovascular Diseases, Metabolic Disorders, GI Diseases and Others (includes corresponding Graph/Chart).....II-16
Select GPCR-Targeting Antibody Drug Candidates in Development.....II-16
1$350
   Select GPCR Antagonists/Agonists in Development for Cancer Treatment.....II-171$100
   Select GCPRs in Development for Non-Cancer Indications.....II-18
Ion Channels.....II-18
Approaches to Drug Discovery in GPCR Space.....II-18
Structure-Based Drug Discovery.....II-18
Ligand-Based Drug Discovery.....II-18
1$100
   Target-Based Drug Discovery.....II-19
GPCR Screening and Targeting Technologies.....II-19
Cell-Based Screening Assays.....II-19
1$100
   Virtual Screening.....II-201$100
   Fragment screening.....II-211$100
   Domain Therapeutics Enters into an Agreement with Merck Serono.....II-22
Anchor Therapeutics Makes a Breakthrough in GPCR Collaboration.....II-22
Receptos Collaborates with Lilly GPCR target.....II-22
1$100
   Sanofi-aventis Enters into Licensing Agreement with Metabolex.....II-23
Neurocrine and Boehringer Ingelheim Join Hands to Develop GPR119 Agonists.....II-23
Affitech Enters into Research Collaboration with NTS Plus.....II-23
1$100
   Takeda Cambridge Inks an Agreement to Utilize Dimerix’ GPCR-HIT Platform.....II-24
PerkinElmer Unveils New Detection Kit for Profiling and Screeing GPCRs.....II-24
Omeros Completes Acquisition of GPCR Assay Technology from Patobios.....II-24
1$100
   DiscoveRx Corporation Takes Over KINOMEscan™.....II-25
Roche and ATCC Collaborate on Real-Time Endogenous GPCR Function Research.....II-25
Millipore Launches Luminescent GPCR Reporter Frozen Cells.....II-25
Ascent Therapeutics re-christened as Anchor Therapeutics.....II-25
Affitech Sells Cancer Vaccine Project to Focus on GPCR Research.....II-25
1$100
   Medarex Releases Pre-clinical Data for MDX-1338.....II-26
Compugen Declares Positive Therapeutic Effects of CGEN-25009.....II-26
Addex Releases Clinical Data for ADX10059.....II-26
Arana Receives Patent Approval for PMX53 and Related GPCR Compounds.....II-26
1$100
   Epix Pharmaceuticals Receives Patent Approval for PRX-03140 and Related
  Compounds.....II-27
Odyssey Thera Receives Patent Approval for Fluorescence-Based Assays.....II-27
Cisbio Bioassays Introduces Cellul'erk Assay.....II-27
DiscoveRx Introduces Products and Services to Assays and Reagents Portfolio.....II-27
1$100
   PerkinElmer Introduces Novel Ion Channel and GPCR Cell Lines.....II-28
Millipore Launches New AllostericProfiler™ Service.....II-28
Ligand Pharmaceuticals and Trevena Enter into Agreement.....II-28
ChanTest Takes Over ACS.....II-28
PerkinElmer Enters into Collaboration with Sangmyung University.....II-28
1$100
   Debiopharm Group Inks Exclusive Agreement with MSM Protein Technologies.....II-29
GVK Biosciences and University of Tokyo Sign Agreement.....II-29
MSM Protein Technologies Enters into Alliance with Merck Serono.....II-29
Xenome Enters into Agreement with Axxam.....II-29
1$100
   DiscoveRx and GlaxoSmithKline Inks Global Agreement.....II-30
Sygnature Enters into Contract Chemistry Agreement with Heptares Therapeutics.....II-30
Enzo Life Sciences Enters into Partnership with BioTek Instruments.....II-30
1$100
   Heptares Therapeutics Enters into Agreement with Novartis Option Fund.....II-31
CellAura Enters into Partnership with Cisbio Bioassays.....II-31
Euroscreen and Novartis Ink Research Collaboration Agreement.....II-31
Evotec Enters into Co-marketing Agreement with DiscoveRx.....II-31
Jubilant Biosys Inks Co-marketing Agreement with DiscoveRx.....II-31
1$100
   Faust Pharmaceuticals Changes Name to Domain Therapeutics.....II-32
GSK, MRCT and DiscoveRx Collaborate for Deorphanization of GPCRs.....II-32
DiscoveRx Inks Agreement with BioFocus.....II-32
Actelion's S1P1 Receptor Agonist to Enter into Phase II Clinical Trial.....II-32
1$100
   AnaSpec Introduces Two Isoform Specific Antibodies.....II-33
Millipore Introduces MultiScreen®HTS+ Filter Plates.....II-33
Faust & Takeda Enter into Research Agreement.....II-33
Caliper Life Sciences Collaborates with DiscoveRx.....II-33
Compugen Inks Agreement with Merck Serono.....II-33
1$100
   BioFocus and Amgen Extend Drug Discovery Agreement.....II-34
DiscoveRx Selects Cosmo Bio to Distribute GPCR Profiling Service across Japan.....II-34
Euroscreen Extends Agreement with Cephalon.....II-34
BioFocus DPI Introduces Novel Version of GPCR SARfari.....II-34
1$100
   PerkinElmer Takes Over Euroscreen Products.....II-351$100
   7TM Pharma A/S (Denmark).....II-36
Actelion Pharmaceuticals Ltd. (Switzerland).....II-36
Acure Pharma AB (Sweden).....II-36
Anchor Therapeutics (USA).....II-36
1$100
   Arena Pharmaceuticals, Inc. (US).....II-371$100
   Addex Pharmaceuticals (Switzerland).....II-38
Acadia Pharmaceuticals Inc., (USA).....II-38
1$100
   Cara Therapeutics, Inc. (USA).....II-39
DiscoveRx Corporation (USA).....II-39
Dimerix Bioscience Pty Ltd (Australia).....II-39
1$100
   Domain Therapeutics (France).....II-40
Euroscreen SA (Belgium).....II-40
1$100
   Trevena, Inc. (USA).....II-411$100
   Table 3: World Recent Past, Current & Future Market Analysis for G-Protein Coupled Receptors (GPCRs) Targeting Drugs Analyzed with Annual Sales Figures in US$ Billion for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-421$350
   Table 4: World Historic Review for G-Protein Coupled Receptors (GPCRs) Targeting Drugs Analyzed with Annual Sales Figures in US$ Billion for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-431$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com